Clinical trials: Systemic Vascular Damage, open to volunteers
EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA
Aim of the study is to identify potential biomarkers, through a proteomic approach, which could be used to evaluate organ damage and predict the response to mepolizumab in a cohort of patients affected by EGPA.
- Conditions
- EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma
- Trial name
- BEOMICS (NCT07343661)
- Testing
- Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
Systemic Vascular Damage
Retinal Microvascularization in OCT-angiography and Systemic Diseases
Systemic diseases are inflammatory, chronic illnesses affecting different organs and altering their function. At present, there are few non-invasive methods for predicting their onset and progression.
- Trial name
- OCTAVA (NCT06613555)
- Testing
- Retinal imaging, Biological check-up
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Centre Hospitalier Universitaire Dijon